Compositional Shift of Gut Microbiome According to the Complications in Patients With Liver Cirrhosis

Sponsor
Chuncheon Sacred Heart Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05786755
Collaborator
(none)
3,000
1
34.8
86.1

Study Details

Study Description

Brief Summary

Change in gut microbiome is closely associated with liver cirrhosis diseases initiation, progression, establishment, and severity. Nevertheless, compositional alterations in gut microbiome during cirrhosis development still not been evaluated, comprehensively. Here, investigators compared the gut microbial composition in cirrhosis patients to encompassing the gut microbial role in whole spectrum of disease.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Stool samples were collected prospectively from 240 participants (Healthy Control (HC=52) + Alcoholic Control (HC=46) + cirrhosis patients (n=142)). 16S rRNA (ribosomal ribonucleic acid) gene sequencing were performed using the MiSeq sequencer on the illumine platform and based on the phylogenetic relationship,16S-based Microbiome Taxonomic Profiling was performed to discovery gut microbial compositional shift along with cirrhosis severity progression.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    3000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Compositional Shift of Gut Microbiome According to the Complications in Patients With Liver Cirrhosis
    Actual Study Start Date :
    Aug 15, 2018
    Actual Primary Completion Date :
    Jun 15, 2021
    Actual Study Completion Date :
    Jul 10, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Healthy Control

    Total number of 52 Healthy Control Included in the study

    Alcoholic Control

    Total number of 46 Alcoholic Control Included in the study

    Only Cirrhosis

    Total 10 patients with only cirrhosis (n= 10, age 66.66±13.51 years) are included in this study

    Cirrhosis+ HCC

    Total 26 patients with Cirrhosis+ hepatocellular carcinoma (HCC) (n= 26, age 61.61±9.85 years) are included in this study

    Cirrhosis+ Varices

    Total 7 patients with Cirrhosis+ Varices (n= 7, age 48.42±15.80 years) are included in this study

    Cirrhosis+ Ascites

    Total number of 26 patients with Cirrhosis+ Ascites (n= 26, age 55.96±8.51years) are included in this study

    Cirrhosis+ 2 Complications

    Total number of 44 patients with cirrhosis with 2 complications (n=44, age 57.84±9.18 years) are included in this study

    Cirrhosis+ 3 Complications

    Total number of 29 patients with cirrhosis and 3 or more complication (n=29, aged 59.64±12.61 years) are included in this study

    Outcome Measures

    Primary Outcome Measures

    1. Gut microbial compositional signature in liver cirrhosis and liver cirrhosis complications. [2 years]

      Gut microbial biomarkers, such as bacterial DNA and metabolic products in the feces, can provide valuable information about the gut microbiome in patients with decompensated cirrhosis, and may be useful in predicting the risk of complications and monitoring disease progression. However, more research is needed to fully understand the role of gut microbiota in decompensated cirrhosis and its complications, and to determine the utility of gut microbial biomarkers as a diagnostic or therapeutic tool in liver cirrhosis and cirrhosis with complications. Therefore, in this clinical trial the investigator will identify cirrhosis dependent bacterial species and metabolites which can have the ability to replace the invasive clinical biomarker for early detection of decompensation in cirrhosis.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    1. Registered in the Hallym University Hospital

    2. Presented initially sign of liver cirrhosis

    3. Patients must have the following laboratory parameters at screening:

    4. Alanine aminotransferase (ALT) ≤10 × upper limit of normal (ULN)

    5. Aspartate aminotransferase (AST) ≤10 × ULN

    6. Hemoglobin ≥12 g/dL for male, ≥11 g/dL for female patients

    7. Platelets ≥ 50,000/mm3

    8. International normalized ratio (INR) ≤1.5 × ULN unless patient has known haemophilia or is stable on an anticoagulant regimen affecting INR.

    9. Albumin ≥3g/dL.

    10. Direct bilirubin ≤1.5 × ULN h) HbA1c ≤10.0%

    1. Creatinine clearance (CLcr) ≥60 mL/min, as calculated by the Cockcroft-Gault equation.
    Exclusion Criteria:
    • Pregnant Female

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital Chuncheon Gangwondo Korea, Republic of 200-704

    Sponsors and Collaborators

    • Chuncheon Sacred Heart Hospital

    Investigators

    • Principal Investigator: Ki Tae Suk, PhD, Chuncheon Sacred Hallym hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Chuncheon Sacred Heart Hospital
    ClinicalTrials.gov Identifier:
    NCT05786755
    Other Study ID Numbers:
    • Liver cirrhosis, gut microbime
    First Posted:
    Mar 28, 2023
    Last Update Posted:
    Mar 28, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 28, 2023